Evolutionary mechanism unifies the hallmarks of cancer

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2012-2021

  Horne, Steven D ^a   Pollick, Sarah A ^a   Heng, Henry H Q ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer evolution; Cancer genomics; Cancer heterogeneity; Evolutionary mechanism of cancer; Genome chaos; Genome instability; Genome theory; Hallmarks of cancer; System inheritance

Indexed keywords

CANCER EVOLUTION; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CELL TRANSFORMATION; DISEASE COURSE; GENE MUTATION; GENOME; HALLMARKS OF CANCER; HUMAN; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GENE; ANIMAL; GENETICS; MOLECULAR EVOLUTION; MUTATION;

ANIMALS; EVOLUTION, MOLECULAR; GENOME; HUMANS; MUTATION; NEOPLASMS;

EID: 84923222640     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29031     Document Type: Review

References (83)

1. Heng HH. Cancer genome sequencing: The challenges ahead. Bioessays 2007;29: 783-94.
2. Rubin H. What keeps cells in tissues behaving normally in the face of myriad mutations? Bioessays 2006;28: 515-24.
3. Weinberg RA. Fewer and fewer oncogenes. Cell 1982;30: 3-4.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144: 646-74.
6. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9: 138-41.
7. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194: 23-8.
8. Liu W, Beck BH, Vaidya KS, et al. Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. Cancer Res 2014;74: 954-63.
9. Heng HH, Bremer SW, Stevens JB, et al. Chromosomal instability (CIN): What it is and why it is crucial to cancer evolution. Cancer Metastasis Rev 2013;32: 325-40.
10. Collado M, Serrano M. Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 2010;10: 51-7.
11. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7: 11-20.
12. Evan GI, d'Adda di Fagagna F. Cellular senescence: Hot or what? Curr Opin Genet Dev 2009; 19: 25-31.
13. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 2009;23: 537-48.
14. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432: 307-15.
15. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res 2008;18: 725-32.
16. Kang HJ, Choi YS, Hong SB, et al. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci 2004;24: 1280-7.
17. Maida Y, Yasukawa M, Furuuchi M, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009;461: 230-5.
18. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 2005;102: 8222-7.
19. Park JI, Venteicher AS, Hong JY, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009;460: 66-72.
20. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer 2010;10: 232-3.
21. Abdallah BY, Horne SD, Stevens JB, et al. Single cell heterogeneity: Why unstable genomes are incompatible with average profiles. Cell Cycle 2013;12: 3640-9.
22. Sonnenschein C, Soto AM. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: A critique. J Biosci 2013;38: 651-63.
23. Kryvenko ON, Jankowski M, Chitale DA, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol 2012;25: 1023-32.
24. Heng HH, Liu G, Stevens JB, et al. Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 2011;98: 242-52.
25. Heng HH, Stevens JB, Bremer SW, et al. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 2011;112: 217-53.
26. Liu G, Stevens JB, Horne SD, et al. Genome chaos: Survival strategy during crisis. Cell Cycle 2014;13: 528-37.
27. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306-13.
28. Pepper JW. Drugs that target pathogen public goods are robust against evolved drug resistance. Evol Appl 2012;5: 757-61.
29. Burrell RA, Swanton C. The evolution of the unstable cancer genome. Curr Opin Genet Dev 2014;24C: 61-7.
30. Heng HH. The conflict between complex systems and reductionism. JAMA 2008;300: 1580-1.
31. Heng HH. Biocomplexity: Challenging reductionism. In: Sturmberg JP, Martin CM, eds. Handbook on systems and complexity in health. New York: Springer, 2013. 193-208.
32. Heng HH, Liu G, Bremer S, et al. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 2006;49: 195-204.
33. Heng HH, Stevens JB, Liu G, et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 2006;208: 461-72.
34. Heng HH, Bremer SW, Stevens J, et al. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 2006;98: 1424-35.
35. Heng HH, Stevens JB, Bremer SW, et al. The evolutionary mechanism of cancer. J Cell Biochem 2010;109: 1072-84.
36. Heng HH, Bremer SW, Stevens JB, et al. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J Cell Physiol 2009; 220: 538-47.
37. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153: 666-77.
38. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144: 27-40.
39. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472: 90-4.
40. Heng HH, Liu G, Stevens JB, et al. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 2013;139: 144-57.
41. Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013;501: 365-72.
42. Heng HH. The genome-centric concept: Resynthesis of evolutionary theory. Bioessays 2009;31: 512-25.
43. Ewald PW, Swain Ewald HA. Toward a general evolutionary theory of oncogenesis. Evol Appl 2013;6: 70-81.
44. Gatenby R. Perspective: Finding cancer's first principles. Nature 2012;491: S55.
45. Merlo LM, Pepper JW, Reid BJ, et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6: 924-35.
46. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell 2014;157: 267-71.
47. Heng HH. Debating cancer: The paradox in cancer research. Singapore: World Scientific Publishing Company, 2014.
48. Horne SD, Chowdhury SK, Heng HH. Stress, genomic adaptation, and the evolutionary tradeoff. Front Genet 2014;5: 92.
49. Stevens JB, Abdallah BY, Liu G, et al. Diverse system stresses: Common mechanisms of chromosome fragmentation. Cell Death Dis 2011;2: E178.
50. Stevens JB, Liu G, Bremer SW, et al. Mitotic cell death by chromosome fragmentation. Cancer Res 2007;67: 7686-94.
51. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: Mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med 2012;18: 1630-8.
52. Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single chromosomes. Cell 2011; 144: 9-10.
53. Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: Paradigm or paradox. Cancer Cell 2012;21: 150-4.
54. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002;8: 1105-14.
55. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: Converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011;10: 57-67.
56. Heng HH, Liu G, Stevens JB, et al. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 2010;11: 1304-16.
57. Stevens JB, Abdallah BY, Liu G, et al. Heterogeneity of cell death. Cytogenet Genome Res 2013; 139: 164-73.
58. Huang S. Genetic and non-genetic instability in tumor progression: Link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev 2013;32: 423-48.
59. Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501: 338-45.
60. Dewhurst SM, McGranahan N, Burrell RA, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 2014;4: 175-85.
61. Nicholson JM, Duesberg P. On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet 2009;194: 96-110.
62. Chen G, Rubinstein B, Li R. Whole chromosome aneuploidy: Big mutations drive adaptation by phenotypic leap. Bioessays 2012;34: 893-900.
63. Ye CJ, Stevens JB, Liu G, et al. Genome based cell population heterogeneity promotes tumorigenicity: The evolutionary mechanism of cancer. J Cell Physiol 2009;219: 288-300.
64. Stevens JB, Horne SD, Abdallah BY, et al. Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev 2013;32: 391-402.
65. Stevens JB, Liu G, Abdallah BY, et al. Unstable genomes elevate transcriptome dynamics. Int J Cancer 2014;134: 2074-87.
66. Pavelka N, Rancati G, Zhu J, et al. Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature 2010; 468: 321-5.
67. Aktipis CA, Boddy AM, Gatenby RA, et al. Life history trade-offs in cancer evolution. Nat Rev Cancer 2013;13: 883-92.
68. Gatenby RA, Gillies RJ, Brown JS. Of cancer and cave fish. Nat Rev Cancer 2011;11: 237-8.
69. Hirte HW. Novel developments in angiogenesis cancer therapy. Curr Oncol 2009;16: 50-4.
70. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15: 392-400.
71. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005;97: 1498-506.
72. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358: 1148-59.
73. Horne SD, Stevens JB, Abdallah BY, et al. Why imatinib remains an exception of cancer research. J Cell Physiol 2013;228: 665-70.
74. Heppner GH. Tumor heterogeneity. Cancer Res 1984;44: 2259-65.
75. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dnamics of neoplastic cells: Simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev 2004;13: 1375-84.
76. Almendro V, Cheng YK, Randles A, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014;6: 514-27.
77. Gorelick R, Heng HH. Sex reduces genetic variation: A multidisciplinary review. Evolution 2011; 65: 1088-98.
78. Heng HH. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome 2007;50: 517-24.
79. Wilkins AS, Holliday R. The evolution of meiosis from mitosis. Genetics 2009;181: 3-12.
80. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-92.
81. Stevens JB, Abdallah BY, Horne SD, et al. Genetic and epigenetic heterogeneity. In: ELS. Chichester: John Wiley & Sons Ltd, 2011.
82. Gatenby RA, Silva AS, Gillies RJ, et al. Adaptive therapy. Cancer Res 2009;69: 4894-903.
83. Silva AS, Kam Y, Khin ZP, et al. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 2012;72: 6362-70.